Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation

Eszter Vanky; Kjell Asmund Salvesen; Henrik Hjorth-Hansen; Kristian Bjerve; Sven Magnus Carlsen

doi:10.1016/j.fertnstert.2005.08.036

Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation

Fertil Steril. 2006 Mar;85(3):770-4. doi: 10.1016/j.fertnstert.2005.08.036.

Authors

Eszter Vanky¹, Kjell Asmund Salvesen, Henrik Hjorth-Hansen, Kristian Bjerve, Sven Magnus Carlsen

Affiliation

¹ Department of Obstetrics and Gynaecology, Norwegian University of Science and Technology, Trondheim, Norway. eszter.vanky@medisin.ntnu.no

PMID: 16500361
DOI: 10.1016/j.fertnstert.2005.08.036

Abstract

In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy. Protein C levels increased slightly in the metformin group compared with the placebo group.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Activated Protein C Resistance / epidemiology
Adult
Antithrombin III / metabolism
Blood Coagulation / drug effects*
C-Reactive Protein / metabolism*
Female
Fibrin Fibrinogen Degradation Products / metabolism
Humans
Hypoglycemic Agents / therapeutic use*
Incidence
Metformin / therapeutic use*
Partial Thromboplastin Time
Polycystic Ovary Syndrome / blood*
Polycystic Ovary Syndrome / drug therapy
Pregnancy
Pregnancy Complications / blood*
Pregnancy Complications / drug therapy
Pregnancy Outcome*

Substances

Fibrin Fibrinogen Degradation Products
Hypoglycemic Agents
Antithrombin III
C-Reactive Protein
Metformin